Targeting IRAK4 in Chronic Lymphocytic Leukemia

NCT07741695 | Not Yet Recruiting

• 1 other identifier: PS-CLL016
• Study Type: observational
• Target: 50
• Locations: 0 countries
• Sites: N/A

Brief Summary

Patients with chronic lymphocytic leukemia (CLL) followed at Strategic Research Program on CLL will be enrolled and undergo sampling of additional amount of blood at the time of standard blood tests. Leukemic B cells and peripheral blood mononuclear cells (PBMC).

Conditions

Chronic Lymphocytic Leukemia (CLL)

Keywords

chronic lymphocytic leukemia; IRAK4

Outcome Measures

Primary Outcomes (1)

• TLR signaling

  In vitro inhibition of TLR signaling in CLL cells following exposure to IRAK4 CDAC, as assessed by modulation of downstream signaling molecules (e.g. phosphorylation status and/or degradation of key components of the TLR pathway).

  12 months

Study Arms (1)

Study cohort

Collection of peripheral blood (up to 50 ml) for the analysis of the biological activity of IRAK4 Chimeric Degradation Activation Compound (CDAC) in purified CLL B cells, assessed by changes in proliferation, apoptosis, and signaling pathway activation following in vitro treatment.

Procedure: Peripheral blood sample collection

Interventions

Peripheral blood sample collection PROCEDURE

Up to 50 ml of blood will be collected for the research project at the time of standard blood tests.

Study cohort

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Adult patients with CLL followed at Strategic Research Program on CLL

You may qualify if:

• Age ≥18 years
• Diagnosis of CLL
• Participant is willing and able to give informed consent for participation in the study.

You may not qualify if:

• \) Participant is unable or unwilling to provide informed consent for participation in the study

Sponsors & Collaborators

• IRCCS San Raffaele: lead

Related Publications (1)

• Delvecchio VS, Sana I, Mantione ME, Vilia MG, Ranghetti P, Rovida A, Angelillo P, Scarfo L, Ghia P, Muzio M. Interleukin-1 receptor-associated kinase 4 inhibitor interrupts toll-like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis. Br J Haematol. 2020 May;189(3):475-488. doi: 10.1111/bjh.16386. Epub 2020 Feb 14.

  PMID: 32057093 BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

Peripheral blood samples

MeSH Terms

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell

Condition Hierarchy (Ancestors)

Leukemia, B-Cell; Leukemia, Lymphoid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Paolo Ghia, MD, PhD

CONTACT

+390226434797; ghia.paolo@hsr.it

Lydia Scarfo, MD

CONTACT

+390226436119; scarfo.lydia@hsr.it

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Prof

Study Record Dates

• First Submitted: July 29, 2026
• First Posted: August 3, 2026
• Study Start (Estimated): September 1, 2026
• Primary Completion (Estimated): September 1, 2027
• Study Completion (Estimated): September 1, 2027
• Last Updated: August 3, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will not share